Los Angeles Capital Management’s Atrium Therapeutics RNA Stock Holding History

Los Angeles Capital Management’s Portfolio RNA Stock Details RNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$423K	Buy	+31,477	New	+$411K	﹤0.01%	958

Other funds holding RNA

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CRCM LP San Francisco, California $152M AUM 26.3% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Los Angeles Capital Management's RNA Position: Q2 2026 in Review

Los Angeles Capital Management opened a new position in Atrium Therapeutics (RNA) in Q2 2026: 31,477 shares worth $423K. The stake represents ﹤0.01% of the portfolio and ranks #958 among its holdings.

155 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

Los Angeles Capital Management held 31,477 shares of Atrium Therapeutics worth $423K as of Q2 2026.
Atrium Therapeutics was a new Los Angeles Capital Management position in Q2 2026.
Atrium Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #958 holding.
155 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.